Professional
Added to YB: 2024-12-10
Pitch date: 2024-11-05
MRK [bullish]
Merck & Co., Inc.
-0.39%
current return
Author Info
No bio for this author
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$248.8B
Pitch Price
$98.65
Price Target
N/A
Dividend
3.39%
EV/EBITDA
8.54
P/E
13.27
EV/Sales
4.24
Sector
Pharmaceuticals
Category
growth
The London Company Income Equity Portfolio Holding: Merck & Co., Inc.
MRK: Keytruda drives growth, but HPV vaccine outlook lowered due to China challenges. Mgmt confident in long-term potential outside China. Strong drug/vaccine pipeline & leadership team's ability to accelerate pipeline & pursue M&A opportunities remain attractive. Solid growth in key areas despite headwinds.
Read full article (1 min)